U.S. Labor Department reports website issues ahead of jobs data release
Investing.com -- Uniphar (LON:UPR) (IR:UPR) delivered solid interim results for the six months to June 30, 2025, posting revenue of €1.49 billion, up 8.6% from a year earlier.
Gross profit rose 6.3% to €219.7 million, translating into organic growth of 8.1%.
Adjusted earnings per share (EPS) climbed 21% to 9.8 cent.
EBITDA edged up 2.9% to €57.5 million, or 4.9% on an organic basis, as all three divisions contributed to growth.
By division, Pharma delivered the strongest performance, with gross profit up 17.6% organically to €64 million, supported by robust demand in Global Sourcing.
Medtech achieved 7.5% organic growth to €57.5 million, aided by portfolio expansion and new market entries.
Supply Chain & Retail grew 3.0% organically to €98.1 million, though EBITDA fell 9% due to higher costs and investments ahead of a new distribution facility.
Group ROCE reached 15.5%, above the medium-term 12–15% target.
Uniphar completed a €35 million share buyback during the period and declared an interim dividend of €0.0071 per share, up 6%.
Net bank debt rose to €197.5 million, reflecting capex spending and the buyback. The group also extended its revolving credit facility to 2029 and secured a new €150 million term loan
Looking ahead, Uniphar reiterated its ambition to grow EBITDA to €200 million by 2028, with at least 80% of that delivered organically.
The group expects continued organic gross profit growth across all divisions, in line with medium-term targets of double-digit growth in Pharma, high-single digits in Medtech, and low-single digits in Supply Chain & Retail.
Chief executive Ger Rabbette said Uniphar “delivered a strong performance in the first half of 2025 with adjusted EPS growth of 21% and gross profit growth of 8.1% with each division delivering in-line with their medium-term targets.”
He added that an “uncompromising focus on solving our healthcare clients’ challenges” underpins confidence in reaching €200 million EBITDA by 2028.